Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
The development of resistance to trastuzumab in HER2-positive gastroesophageal cancer remains a problem. The use of dual HER2 blockade to overcome this is a therapeutic strategy that should be researched more extensively.
Saved in:
Main Authors: | Von Cheong, E., Ho, Gwo Fuang |
---|---|
Format: | Article |
Published: |
Wiley
2021
|
Subjects: | |
Online Access: | http://eprints.um.edu.my/34953/ |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Chemotherapy-induced nausea and vomiting for healthcare professional
by: Lua, Prof. Dr. Pei Lin
Published: (2019) -
Real-world treatment and outcomes of ALK-positive metastatic non-small cell lung cancer in a Southeast Asian country
by: Poh, Mau Ern, et al.
Published: (2023) -
Total body irradiation or chemotherapy conditioning in childhood ALL: A multinational, randomized, noninferiority phase III study
by: Peters, Christina, et al.
Published: (2021) -
Exploring the ‘Dormancy Activation Switch’ in the tumour microenvironment for metastatic lung cancer: The possible role of MicroRNA
by: Amnani, A., et al.
Published: (2021) -
Epithelial-to-mesenchymal transition (EMT) to sarcoma
in recurrent lung adenosquamous carcinoma following
adjuvant chemotherapy
by: Chai, Chee-Shee, et al.
Published: (2019)